Equillium (0FY) Price & Analysis

0 Followers

0FY Stock Chart & Stats

€1.63

€0.03(3.78%)

At close: Jan 08 4:00 PM EST

€1.63

€0.03(3.78%)

Day’s Range― - ―

52-Week Range€0.25 - €2.73

Previous CloseN/A

Volume0.00

Average Volume (3M)865.00

Market Cap

€169.36M

Enterprise Value€45.58M

Total Cash (Recent Filing)€61.32M

Total Debt (Recent Filing)€692.00K

Price to Earnings (P/E)―

Beta-1.23

Next Earnings

Aug 12, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding63,226,555

10 Day Avg. Volume250

30 Day Avg. Volume865

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)4.98

Price to Sales (P/S)0.00

P/FCF Ratio-6.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€6.67

Price Target Upside308.98% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-0.2

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageExtremely low debt reduces bankruptcy and interest‑service risk and gives management flexibility to prioritize R&D without fixed debt obligations. For a clinical‑stage biotech this durable balance‑sheet strength supports multi‑quarter development programs and partner negotiations.

Recent Financing Extends RunwayA material private placement that meaningfully extends cash runway reduces immediate liquidity pressure and allows planned clinical work to proceed. That financing lowers short‑term funding risk and increases the chance of hitting development milestones that enable partnering or licensing over the coming months.

Focused Clinical‑stage PipelineA clear scientific focus on immunomodulatory biologics and a lead monoclonal program provides a coherent strategy likely to attract partners or acquirers. Pipeline concentration on validated immune targets offers structural commercial upside if clinical results are positive and supports long‑term asset value creation.

Bears Say

Near‑zero RevenueThe abrupt loss of commercial/partnered revenue leaves the company without meaningful organic cash generation. Absent product sales or recurring licensing receipts, Equillium must rely on external financing to fund R&D, making long‑term program execution and independence contingent on successful capital raises or partnerships.

Heavy Cash BurnSustained negative operating and free cash flow indicates persistent funding needs and pressure on liquidity if financing stalls. Ongoing burn forces prioritization of programs, can delay trials, and raises the probability of disruptive financing decisions that affect long‑term execution and strategic optionality.

Capital Structure Dilution RiskBoard approvals to increase authorized shares and permit a wide reverse split range create clear capacity for future equity issuance and price management. This structural flexibility raises the likelihood of dilution over time, which can erode existing holders' ownership and complicate long‑term shareholder alignment.

Equillium News

Equillium Shareholders Approve Reverse Split and Capital Changes

Equillium ( ($EQ) ) has shared an announcement. On May 28, 2026, Equillium, Inc. held its 2026 annual...

1M ago

Equillium price target raised to $7 from $6 at Raymond James

Raymond James raised the firm’s price target on Equillium (EQ) to $7 from $6 and keeps a Strong...

1M ago

Leerink upgrades Equillium on ‘supportive’ ulcerative colitis data

Leerink upgraded Equillium (EQ) to Outperform from Market Perform with a price target of $6, up from $1....

1M ago

Equillium upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Equillium (EQ) to Outperform from Market Perform with a $6 price target Published first on TheFly...

1M ago

Equillium: Compliance, Operational and Market Risks Cloud Long-Term Outlook for Shareholders

Equillium (EQ) has disclosed a new risk, in the Regulation category. Equillium faces ongoing exposure to U.S. public...

2M ago

Equillium reports Q1 EPS (6c), consensus (4c)

“Following our March year-end update and financing, we have remained focused on advancing EQ504 toward the clinic while...

2M ago

Equillium appoints Snehal Naik as chief development officer

Equillium (EQ) appointed Snehal Naik as chief development officer. Naik will lead clinical development and medical strategy across...

2M ago

Equillium initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Equillium (EQ) with an Outperform rating and $7 price target The firm is positive...

2M ago

Equillium initiated with a Buy at B. Riley

B. Riley analyst William Wood initiated coverage of Equillium (EQ) with a Buy rating and $6 price target...

2M ago

Equillium initiated with a Strong Buy at Raymond James

Raymond James initiated coverage of Equillium (EQ) with a Strong Buy rating and $6 price target Lead asset...

3M ago

Equillium files to sell 18.88M shares of common stock for holders

17:14 EDT Equillium (EQ) files to sell 18.88M shares of common stock for holders Published first on TheFly...

3M ago

Cantor starts Equillium at Overweight on ulcerative colitis potential

Cantor Fitzgerald initiated coverage of Equillium (EQ) with an Overweight rating and $10 price target The company’s lead...

3M ago

EQ Upcoming Earnings Report: What to Expect?

Equillium (EQ) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street analysts expect...

3M ago

Equillium Raises Capital Through Private Equity Securities Sale

Equillium ( ($EQ) ) just unveiled an announcement. On March 11, 2026, Equillium, Inc. entered into a securities...

4M ago

0FY FAQ

What was Equillium Inc’s price range in the past 12 months?

Equillium Inc lowest stock price was €0.25 and its highest was €2.73 in the past 12 months.

What is Equillium Inc’s market cap?

Equillium Inc’s market cap is €169.36M.

When is Equillium Inc’s upcoming earnings report date?

Equillium Inc’s upcoming earnings report date is Aug 12, 2026 which is in 44 days.

How were Equillium Inc’s earnings last quarter?

Equillium Inc released its earnings results on May 13, 2026. The company reported -€0.052 earnings per share for the quarter, missing the consensus estimate of -€0.04 by -€0.012.

Is Equillium Inc overvalued?

According to Wall Street analysts Equillium Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Equillium Inc pay dividends?

Equillium Inc does not currently pay dividends.

What is Equillium Inc’s EPS estimate?

Equillium Inc’s EPS estimate is -0.05.

How many shares outstanding does Equillium Inc have?

Equillium Inc has 63,226,555 shares outstanding.

What happened to Equillium Inc’s price movement after its last earnings report?

Equillium Inc reported an EPS of -€0.052 in its last earnings report, missing expectations of -€0.04. Following the earnings report the stock price went up 5.337%.

Which hedge fund is a major shareholder of Equillium Inc?

Currently, no hedge funds are holding shares in DE:0FY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Equillium Stock Smart Score

Neutral

Fundamentals

Return on Equity

-61.43%

Trailing 12-Months

Asset Growth

277.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Equillium Inc

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

Equillium (0FY) Earnings & Revenues

Historic Earnings Reports

0FY Stock 12 Month Forecast

Average Price Target

€6.67

▲(308.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","5":"€5","8":"€8","11":"€11","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10.5655194,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€10.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.666339621428571,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.40229975,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,3.074270723076923,3.6985414461538464,4.32281216923077,4.947082892307693,5.5713536153846155,6.195624338461538,6.819895061538462,7.444165784615385,8.068436507692308,8.69270723076923,9.316977953846155,9.941248676923077,{"y":10.5655194,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,2.774333817032967,3.098667634065934,3.423001451098901,3.747335268131868,4.071669085164835,4.396002902197802,4.720336719230769,5.044670536263736,5.3690043532967024,5.693338170329669,6.017671987362636,6.342005804395603,{"y":6.666339621428571,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,2.600176903846154,2.7503538076923078,2.9005307115384618,3.0507076153846153,3.2008845192307693,3.3510614230769233,3.501238326923077,3.651415230769231,3.801592134615385,3.9517690384615385,4.101945942307692,4.2521228461538465,{"y":4.40229975,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.32,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.198,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.206,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.188,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.278,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.452,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.622,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.655,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >